Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...
17hon MSN
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
18hon MSN
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact
Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback